<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01870674</url>
  </required_header>
  <id_info>
    <org_study_id>YH12852-101</org_study_id>
    <nct_id>NCT01870674</nct_id>
  </id_info>
  <brief_title>Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH12852 After Oral Administration in Healthy Male Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo/Active-controlled, Single/Multiple Dose Phase 1 Clinical Study to Investigate the Safety/Tolerability and PK/PD of YH12852 After Oral Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to evaluate the safety/tolerability and pharmacokinetics/pharmacodynamics(PK/PD)of&#xD;
      YH12852 after oral administration in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of adverse events, seriousness of adverse event</measure>
    <time_frame>D1~Post study visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>significant changes in vital sign</measure>
    <time_frame>D1~Post study visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>significant changes in 12-lead electrocardiography</measure>
    <time_frame>D1~Post study visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>significant changes in laboratory test</measure>
    <time_frame>D1~Post study visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>significant physical exam</measure>
    <time_frame>D1~Post study visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>0~48 hrs(SAD,FSD cohorts), 0~24 hrs/D5,6 0hr/D7 0~48hrs(MAD cohort)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
    <time_frame>0~48 hrs(SAD,FSD cohorts), 0~24 hrs/D5,6 0hr/D7 0~48hrs(MAD cohort)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae</measure>
    <time_frame>0~48 hrs(SAD cohort), 0~24 hrs/D7 0~48hrs(MAD cohort)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BSFS</measure>
    <time_frame>D1~7(SAD, FSD cohorts), D1~14(MAD cohort)</time_frame>
    <description>pharmacodynamics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of defecation</measure>
    <time_frame>D1~7(SAD, FSD cohorts), D1~14(MAD cohort)</time_frame>
    <description>pharmacodynamics</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">127</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>YH12852</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>&lt;SAD cohort&gt;&#xD;
Experimental: YH12852 1mg/single dose, qd&#xD;
Experimental: YH12852 3mg/single dose, qd&#xD;
Experimental: YH12852 10mg/single dose, qd&#xD;
&lt;FSD cohort&gt;&#xD;
Experimental: YH12852 0.5mg/single dose, qd&#xD;
Experimental: YH12852 1mg/single dose, qd&#xD;
Experimental: YH12852 2mg/single dose, qd&#xD;
Experimental: YH12852 3mg/single dose, qd&#xD;
&lt;MAD cohort&gt;&#xD;
Experimental: YH12852 0.5mg/repeat dose, qd&#xD;
Experimental: YH12852 1mg/repeat dose, qd&#xD;
Experimental: YH12852 2mg/repeat dose, qd&#xD;
Experimental: YH12852 3mg/repeat dose, qd&#xD;
Each dosing group(except MAD cohort 0.5mg which has single treatment arm taking YH12852 only) contains 12 subjects. 12 subjects are administered YH12852 or placebo/active comparators.(YH12852:placebo:active=8:2:2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prucalopride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&lt;each cohort&gt; Prucalopride succinate 1.321mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>&lt;each cohort&gt; Matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852</intervention_name>
    <arm_group_label>YH12852</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prucalopride</intervention_name>
    <arm_group_label>Prucalopride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  healthy male/female aged 19 to 45 with body mass index(BMI) between 18 and 25kg/m2&#xD;
&#xD;
          -  Subject who has no congenital, chronic disease and disease symptoms in medical&#xD;
             examination result&#xD;
&#xD;
          -  Subject who is judged to be eligible by principal investigator or sub-investigator&#xD;
             according to various reasons including their abnormal test results(clinical laboratory&#xD;
             test, 12-lead ECG etc)&#xD;
&#xD;
          -  Subjects who has signed a written informed consent voluntarily,prior to any procedure,&#xD;
             using a form that is approved by the local Institutional Review Board after detail&#xD;
             explanation of the purpose, contents, and characteristic of the drug&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject who has history or presence of clinically significant diseases in liver,&#xD;
             kidney, gastrointestinal tract, nervous system, respiratory system, endocrine system,&#xD;
             blood tumor, cardiovascular, urinary system, and mental disorder&#xD;
&#xD;
          -  Subject who is hypersensitive to components contained in YH12852 or prucalopride or&#xD;
             aspirin/antibiotics like drugs&#xD;
&#xD;
          -  Medical history of gastrointestinal disease or acid restraining surgery, gastric/&#xD;
             esophagus surgery(excluding appendectomy, hernia surgery)&#xD;
&#xD;
          -  Clinically significant abnormal values in diagnostic check within 28 days before the&#xD;
             treatment(&gt;1.25 fold of normal upper limit in the levels of AST or ALT, &gt;1.5 fold of&#xD;
             normal upper limit in the levels of Total bilirubin, &lt; 80ml/min of Cockcroft-Gault&#xD;
             used creatinine clearance&#xD;
&#xD;
          -  Subject has over QTc interval of 550 ms or PR interval of 210 ms or QRS interval of&#xD;
             120 ms or QT interval of 500 ms on baseline 12-lead ECG, as determined by the&#xD;
             Investigator&#xD;
&#xD;
          -  Subject who had taken usual dose of any prescription drugs within 14 days before the&#xD;
             treatment or who had used usual dose of OTC drugs within 7 days before the treatment&#xD;
&#xD;
          -  Subject who participated in another clinical trail within 2 months before enrolling in&#xD;
             this study&#xD;
&#xD;
          -  subject who donated whole blood within 2 months or component blood within 1 month&#xD;
             before the treatment&#xD;
&#xD;
          -  Medically unacceptable contraception used during the clinical trial&#xD;
&#xD;
          -  Subject who drank over 30g/day or were detected alcohol positive on test&#xD;
&#xD;
          -  Subject who stopped smoking within 3 months before the treatment or weren't able to&#xD;
             stop smoking during the hospitalization&#xD;
&#xD;
          -  Subject who had a beverage containing caffeine during the hospitalization&#xD;
&#xD;
          -  Subjects with clinically significant observations considered as unsuitable based on&#xD;
             medical judgment by investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje Busan Paik hospital</name>
      <address>
        <city>Busan</city>
        <zip>614-735</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>May 20, 2013</study_first_submitted>
  <study_first_submitted_qc>June 3, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <last_update_submitted>May 7, 2015</last_update_submitted>
  <last_update_submitted_qc>May 7, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>safety</keyword>
  <keyword>tolerability</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prucalopride</mesh_term>
    <mesh_term>YH12852</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

